FDA’s One-Day Inspection Assessments Are Here!
On May 6, 2026, the Food and Drug Administration (FDA) announced piloting one-day inspection assessments as part of their broader initiative to make the Agency’s inspection resources more targeted and efficient. Rather than replacing traditional inspections, the pilot program introduces shorter, targeted screening assessments designed to expand surveillance coverage, gather risk-relevant data, and provide faster feedback to selected facilities. For manufacturers in the medical device, biologics/human cells, tissues, and cellular and tissue based products (HCT/Ps), and drug sectors, the message shows FDA is refining a more risk-based oversight model and companies should be ready to perform under a focused, risk based data-driven inspection format as well as under conventional multi-day inspections.
According to the FDA’s announcement, the agency launched a pilot in April 2026 to conduct one-day inspectional assessments as a complement to standard inspections. These assessments are intended to be shorter, focused screening exercises that help the Agency use its inspection resources more efficiently while broadening surveillance across facilities. These facilities are being selected using risk-based criteria such as product type, prior inspection outcomes, and operational characteristics. As of late April 2026, the Agency had completed approximately forty-six (46) one- day assessments, with most resulting in “No Action Indicated (NAI)” outcomes [1] . FDA also emphasized that these assessments do not replace standard inspections, do not change enforcement policy, and may be extended if investigators identify significant observations.
Although these visits may be shorter, they can still carry real consequences. Manufacturers should expect investigators to arrive with a specific purpose as they will likely focus on a limited set of systems, records, or operations, and move quickly to see whether your site matches the Agency’s expectations. If your team is organized, that can work in your favor but if you’re slow to retrieve, your answers are inconsistent, or your actual operations do not match your filings, the visit can quickly expand into something more serious. These assessments are also data collection tools. The FDA said it is looking at recurring compliance themes, site-specific risk scores, and gaps between registered operations and what investigators see onsite. This means that even a short visit can affect how FDA views your facility later.
How does this affect multiple industries? Here are a few areas to consider:
For medical device companies, execution is a pressure point. The FDA will want to see that your quality system works in practice across design, production, complaints, and post-market follow-up.
For biologics/HCT/P establishments, clarity matters! Be ready to show how products are classified, how donor eligibility is handled, and how processing controls fit the regulatory framework that applies to your site. Expect focus on documentation, contamination control, deviation handling, and whether your team can clearly explain complex processes.
For drug manufacturers, this is likely to mean close attention to data integrity, batch records, investigations, CAPA effectiveness, and how well your quality unit makes timely, risk-based decisions.
There is a real opportunity here for companies that are well run, as a shorter visit can mean less disruption and faster feedback. On the downside, a compressed visit leaves little room to recover from weak records, unclear responsibilities, or sloppy answers. For some facilities, the one-day format may feel tougher, not easier. The message from FDA is straightforward; expect a more agile inspection model and more selective oversight. The one-day assessment doesn’t lower the bar, instead it raises the premium on being organized, accurate, and ready to prove control fast. The smart move is to prepare now and be ready from hour one!
Have you “pressure-tested” your system for inspection readiness? If not, reach out and let the Solaris team help you prepare! Contact us here!
Check back next time as we keep up with industry trends!